November 24, 2021 06:56 AM ESTUpdated 10:25 AM
Pharma
Coronavirus

Eu­rope changes its tune on Covid-19 vac­cine IP, ad­vo­cat­ing now for a 'tar­get­ed waiver'

Zachary Brennan

Senior Editor

Just a month af­ter it seemed like ne­go­ti­a­tions were get­ting nowhere fast on waiv­ing the in­tel­lec­tu­al prop­er­ty around Covid-19 vac­cines ahead of a De­cem­ber …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times